150 related articles for article (PubMed ID: 24990113)
1. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects.
Xu H; O'Gorman M; Boutros T; Brega N; Kantaridis C; Tan W; Bello A
J Clin Pharmacol; 2015 Jan; 55(1):104-13. PubMed ID: 24990113
[TBL] [Abstract][Full Text] [Related]
2. Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects.
Johnson TR; Tan W; Goulet L; Smith EB; Yamazaki S; Walker GS; O'Gorman MT; Bedarida G; Zou HY; Christensen JG; Nguyen LN; Shen Z; Dalvie D; Bello A; Smith BJ
Xenobiotica; 2015 Jan; 45(1):45-59. PubMed ID: 25034009
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
[TBL] [Abstract][Full Text] [Related]
6. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
[TBL] [Abstract][Full Text] [Related]
7. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
8. Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects.
Lau YY; Gu W; Lin T; Song D; Yu R; Scott JW
J Clin Pharmacol; 2016 May; 56(5):559-66. PubMed ID: 26272586
[TBL] [Abstract][Full Text] [Related]
9. First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium.
Balis FM; Thompson PA; Mosse YP; Blaney SM; Minard CG; Weigel BJ; Fox E
Cancer Chemother Pharmacol; 2017 Jan; 79(1):181-187. PubMed ID: 28032129
[TBL] [Abstract][Full Text] [Related]
10. Relative Bioavailability and Food Effect Evaluation for 2 Tablet Formulations of Asciminib in a 2-Arm, Crossover, Randomized, Open-Label Study in Healthy Volunteers.
Menssen HD; Quinlan M; Kemp C; Tian X
Clin Pharmacol Drug Dev; 2019 Apr; 8(3):385-394. PubMed ID: 30059193
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
Hibma JE; O'Gorman M; Nepal S; Pawlak S; Ginman K; Pithavala YK
Cancer Chemother Pharmacol; 2022 Jan; 89(1):71-81. PubMed ID: 34698901
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B
J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
Frohna P; Lu J; Eppler S; Hamilton M; Wolf J; Rakhit A; Ling J; Kenkare-Mitra SR; Lum BL
J Clin Pharmacol; 2006 Mar; 46(3):282-90. PubMed ID: 16490804
[TBL] [Abstract][Full Text] [Related]
14. The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Tugnait M; Gupta N; Hanley MJ; Venkatakrishnan K; Sonnichsen D; Kerstein D; Dorer DJ; Narasimhan N
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):734-741. PubMed ID: 30570839
[TBL] [Abstract][Full Text] [Related]
15. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.
Ahmad M; Pervaiz F
Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997
[TBL] [Abstract][Full Text] [Related]
16. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
Henney HR; Shah J
Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
Nguyen L; Holland J; Mamelok R; Laberge MK; Grenier J; Swearingen D; Armas D; Lacy S
J Clin Pharmacol; 2015 Nov; 55(11):1293-302. PubMed ID: 25907407
[TBL] [Abstract][Full Text] [Related]
18. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
Xu H; O'Gorman M; Tan W; Brega N; Bello A
Eur J Clin Pharmacol; 2015 Dec; 71(12):1441-9. PubMed ID: 26381275
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
Meneses-Lorente G; Bentley D; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Brink A; Djebli N; Mercier F; Buchheit V; Phipps A
Invest New Drugs; 2021 Jun; 39(3):803-811. PubMed ID: 33462752
[TBL] [Abstract][Full Text] [Related]
20. The renal effects of ALK inhibitors.
Izzedine H; El-Fekih RK; Perazella MA
Invest New Drugs; 2016 Oct; 34(5):643-9. PubMed ID: 27468827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]